Evidence map›Paper›PMID 36082449›Full record

ArticleInternational journal of cancer2023

Global colorectal cancer research, 2007-2021: Outputs and funding.

Mursheda Begum, Grant Lewison, Xiang Wang, Philip D Dunne, Tim Maughan, Richard Sullivan, Mark Lawler

Open access · hybridAbstract read
In one paragraph

Article in International journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Mursheda BegumQueen Mary University of London, School of Business and Management, London, UK.
Grant LewisonKing's College London, Institute of Cancer Policy, Guy's Hospital, London, UK.ORCID 0000-0002-4493-1216
Xiang WangDepartment of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
Philip D DunneFaculty of Medicine, Patrick G Johnston Centre for Cancer Research, Health and Life Sciences, Queen's University Belfast, Belfast, UK.
Tim MaughanMRC Oxford Institute for Radiation Oncology Gray Laboratories, University of Oxford, Oxford, UK.
Richard SullivanKing's College London, Institute of Cancer Policy, Guy's Hospital, London, UK.
Mark LawlerFaculty of Medicine, Patrick G Johnston Centre for Cancer Research, Health and Life Sciences, Queen's University Belfast, Belfast, UK.
Guy's Hospital · GBQueen's University Belfast · GBChinese Academy of Medical Sciences & Peking Union Medical College · CNQueen Mary University of London · GBUniversity of Oxford · GB

Funding

Cancer Research UKMedical Research Council GACDRE19691
6 · The paper itself

Abstract

The purpose of this study was to provide an evidence base for colorectal cancer research activity that might influence policy, mainly at the national level. Improvements in healthcare delivery have lengthened life expectancy, but within a situation of increased cancer incidence. The disease burden of CRC has risen significantly, particularly in Africa, Asia and Latin America. Research is key to its control and reduction, but few studies have delineated the volume and funding of global research on CRC. We identified research papers in the Web of Science (WoS) from 2007 to 2021, and determined the contributions of the leading countries, the research domains studied, and their sources of funding. We identified 62 716 papers, representing 5.7% of all cancer papers. This percentage was somewhat disproportionate to the disease burden (7.7% in 2015), especially in Eastern Europe. International collaboration increased over the time period in almost all countries except in China. Genetics, surgery and prognosis were the leading research domains. However, research on palliative care and quality-of-life in CRC was lacking. In Western Europe, the main funding source was the charity sector, particularly in the UK, but in most other countries government played the leading role, especially in China and the USA. There was little support from industry. Several Asian countries provided minimal contestable funding, which may have reduced the impact of their CRC research. Certain countries must perform more CRC research overall, especially in domains such as screening, palliative care and quality-of-life. The private-non-profit sector should be an alternative source of support.

Indexed as

Biomedical ResearchColorectal NeoplasmsAsiaDelivery of Health CareEuropeHumanscolorectal cancerdisease burdenfundingresearch domainsresearch outputs

Identifiers

PMID36082449
PMCPMC10086800
OpenAlexW4295079295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.